1. Home
  2. IXHL

as of 10-19-2026 3:16pm EST

$2.77
$0.05
-1.95%
Stocks Nasdaq

Incannex Healthcare Inc is a clinical-stage biopharmaceutical development company dedicated to developing inventive medicines for patients living with serious chronic diseases and unmet needs. The Company's drug candidates include IHL-42X for the treatment of obstructive sleep apnea (OSA) and PSX-001, the Company's psilocybin treatment in combination with psychological therapy in development to treat patients with generalized anxiety disorder (GAD). The Company also has a drug candidate, IHL-675A, for the treatment of rheumatoid arthritis. Each of these programs target conditions that currently have limited, inadequate, or no approved pharmaceutical treatment options. The Company continues to evaluate strategies for IHL-675A when and as resources permit.

Founded: 2001 Country:
Australia
Australia
Employees: 12 City: NORWEST NSW
Market Cap: 35.4M IPO Year: 2024
Target Price: N/A AVG Volume (30 days): 54.6K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: annual
EPS: -1.66 EPS Growth: -22.96
52 Week Low/High: $0.15 - $6.39 Next Earning Date: 11-13-2026
Revenue: $12,000 Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: -1.70 Index: N/A
Free Cash Flow: -12877000.0 FCF Growth: N/A

AI-Powered IXHL Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Precision: 0.00%
0.00%
AI Precision

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: